Navigation Links
New non-surgical treatment for common, vexing eye condition
Date:3/31/2014

Baltimore, MD, 31 March 2014. A new report reveals a potential breakthrough in the treatment of a common eye ailment known as pterygium (Surfer's eye) that impacts the vision, eye health, and cosmetic appearance of countless sufferers.

The newly published report shows that eye drops containing the anti-anginal drug dipyridamole (Persantin, Cardoxin) led to almost total disappearance of an inflamed pterygium in a 35 year old otherwise healthy woman.

Dipyridamole is a drug in use over the past 55 years to treat other disorders, but now found to have this remarkable new use.

Pterygium is a disorder in which a non-cancerous growth develops on the white conjunctiva of the eye and over time invades the cornea. In some countries it affects up to 25% of the population. As the growth spreads, patients can develop vision problems as well as significant discomfort from complications such as dry eye, inflammation, irritation, and foreign body sensation. Additionally, because of their location in the eyes, pterygia are a cause of substantial cosmetic concern for sufferers.

Until now, eye surgery has been the only curative option, aided by medications trying to lessen the disorder's symptoms. However, even after eye surgery, pterygia often recur.

The new report's lead author, Moshe Rogosnitzky, who is Co-Founder and Director of Research at the MedInsight Research Institute, discovered that administration of dipyridamole eye drops significantly reduced a pterygium and completely resolved the associated inflammation and other symptoms.

Clinical trials are now being plannedfor pterygia, pingueculae, and other common eye disorders and their complications such as dry eye and inflammation.

One particular advantage to this discovery is that dipyridamole is a widely-approved anti-thrombosis medication that has been in use for over 55 years. Its safety profile is well-established; as such, fast-track development of dipyridamole eye drops as a repurposed drug is feasible.

Moshe Rogosnitzky commented on this finding, "Pterygium and dry eye are debilitating disorders for which new safe solutions are urgently needed, and I believe dipyridamole has the potential to provide relief to sufferers of these intractable conditions.

Rogosnitzky, who specializes in finding new uses for old drugs, continued, "This is yet another example of the advantages of drug repurposing. Whereas bringing a new drug to market can take up to 17 years or more, finding a new use for an old drug with an excellent safety profile can lead to approval and availability in as little as two years."


'/>"/>
Contact: Deena Illions
deena1@medinsight.org
443-927-7755
MedInsight Research Institute
Source:Eurekalert  

Related medicine news :

1. Masha Banar, Board Certified Physician Associate, Now Offers Non-Surgical Rhinoplasty for Correction of Complications After Surgical Rhinoplasty
2. Cosmetic Laser Institute in Orange County Introduces Non-Surgical Fat Reduction with Exilis
3. Barnes-Jewish Hospital Offering New FDA-approved Non-surgical Procedure for Mitral Valve Repair
4. Lipo Body Sculpture of Houston Announces Breakthrough Treatment for Non-Surgical Neck Tightening
5. Masha Banar, PA-C of Visage Sculpture, Non-surgical Face Shaping Cosmetic Practice of Boston, Confirms Resistance Forming to Botox over Time, Less to Dysport.
6. Non-surgical Facelift, Specialty of Masha Banar PA-C of Visage Sculpture, Got a "Lift": Retrospective Comparison of Radiesse, Sculptra, and Perlane
7. Horwitz Dermatology Now Offers Non-Surgical Ultrasound Skin Tightening Treatments
8. Brandith Irwin, MD, of SkinTour.com Answers New Blog Question About Improving Neck Skin Non-Surgically
9. Visage Sculpture, Non-Surgical Face Shaping Cosmetic Practice of Boston, Announces Using Microcannulas to Make Non-Surgical Rhinoplasty Safer
10. Living Well Medical Introduces Groundbreaking Non-Surgical Therapies for Osteoarthritis Knee Pain
11. Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New non-surgical treatment for common, vexing eye condition
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology: